Multicentre Perspective Non-interventional Study of Survival Benefits of iCAGES-guided Therapy in Contrast to Standard Therapy or IHC-guided Therapy for Advanced Cancers
| Registry | NCT03192501 |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Enrollment | 250 (Estimated) |
| Sponsor | Second Affiliated Hospital of Guangzhou Medical University (Other); collaborators: The First Affiliated Hospital of Guangzhou Medical University, Sun Yat-sen University |
| Conditions | Lung Cancer, Gene Abnormality, Gene Product Sequence Variation, Cancer |
| Interventions | inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group. (Drug) |
| Dates | start 2017-07-01, primary completion 2030-07-01 (estimated), completion 2039-07-01 (estimated), first posted 2017-06-20, last updated 2024-06-25 |
| Locations | 1 site in China |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Lung Cancer All trials for Gene Abnormality All trials of inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.
This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.
Cancer is a fatal disease caused by the accumulation of various oncogene and tumor suppressor gene mutations. Studies of high-throughput sequencing for patients who suffered from cancer has found that different mutations play a different role in the occurrence and development of different cancers. Several gene panels already exist to help identify mutations in a few genes that may have corresponding FDA-approved drugs or drugs under clinical trials. However, given whole-genome/exome sequencing data, the suitable clinical analysis tool to analyze individualized cancer-related gene mutations, and recommend the most appropriate targeted treatment options among hundreds of possible drugs therapy is absent currently.
The recently proposed iCAGES is a precise biomedical informatics analysis tool, which could help increase the accuracy of cancer driver gene detection and prioritization, bridge the gap between personal cancer genomic data and prior cancer research knowledge,and facilitate cancer molecular diagnosis as well as personalized precision therapy.
IHC detection of multiple molecules such as EGFR, HER2-3, TROP3, NECTIN4, MET, B7-H3-4, B1-H7, Claudin18.2, FGFR1-4, Mesothelin, ROR1, BCMA, AXL, TF, FRα, CD70, PPARα, HIF-2α, RET, ROS1, NTRK, CDK4/6, FLT3, EZH2 are also scheduled for appropriate targeted therapy and comparison if available.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Study group (A group) | Drug: inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group. | In this group, we perform whole exome or genome sequencing of tumor sample in compared to blood sample, screen tumor-related special mutations by using biomedical informatics analysis procedure and utilized the iCAGES system to rank the most appropriate drugs available and then manually examine this list to select the best therapeutic strategy for the patient based on availability of drug and expert knowledge. The PFS, OS, and quality of life (QOL) will be recorded and compared with that from standard care. | |
| Control group (B group) | In this group, patients with advanced cancers (matched with Group A) will be treated under the guidance of NCCN, without performing iCAGES analysis. | ||
| Control group (C group) | Drug: inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group. | In this group, patients with advanced cancers (matched with Group A) will be treated with appropriate targeted drugs according to IHC detection of more than 20 protein molecules with blank tissue slides from the cancer. |
Sex: All, ages: 18 Years to 70 Years
Inclusion Criteria: * Pathological and clinical diagnosis of recurrence / metastatic lung cancer or other advanced cancers. * There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals. * The patient is informed consent and signed a written consent. Exclusion Criteria: * Age > 70 or <18 years old. * Previous history of malignant tumors. * Pregnant or lactating female patients. * Any serious concomitant disease that is expected to have an adverse effect on prognosis, including the heart disease that treatment is required, unsatisfactory controlled diabetes and psychiatric disorders.
| Facility | City | Country | Status |
|---|---|---|---|
| The Second Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong | China | Recruiting |